BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments
Summary
SAN CARLOS, Calif.--(BUSINESS WIRE)--BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreessen Horowitz, with participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors. Leveraging recent advances in synthetic biology and machine learning, our platform measures and optimizes antibodies for the biophysical and functional properties needed for cutting-edge therapeutic applications,” said BigHat Co-founder and CEO Mark DePristo, PhD. “The relevant search space for protein therapeutics is orders of magnitude larger than a purely experimental approach anchored in naturally-occurring sequences can efficiently traverse,” said Vineeta Agarwala, General Partner at Andreessen Horowitz. The company was also awarded a Small Business Innovation Research (SBIR) grant for improving protein production from the National Institute of Standards and Technology (NIST). In BigHat’s wet lab, the platform increases throughput, speeds the feedback loop and really eliminates some of the cost and time barriers standing in the way of optimizing protein therapeutics,” said Francisco Gimenez, Partner at 8VC.
Funding
Review available funding amount, funding date, investors, and linked company information related to BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments in the interactive ISVWorld profile.